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Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is one of the most 
common neurological disorders that significantly affects quality of life and sleep. It manifests itself in 
involuntary movements of the lower limbs due to the feeling of discomfort and restlessness that 
patients feel in their lower limbs.  
RLS is of great interest to the experts in various fields of medicine, especially to neurologists, 
general practitioners, internists and psychiatrists. Numerous clinical conditions and diseases play a 
role in the pathophysiology of RLS. Some of them are pregnancy, some kidney and stomach 
diseases, iron deficiency and some disorders of the metabolism.  
Moreover, iron is a very important micronutrient in the human body. It is involved in many 
metabolic processes and, in addition to RLS, it is also associated with other diseases such as 
hemochromatosis and anemia. This neurological disorder has wide therapeutic choices, which 
include lifestyle changes, dopaminergic agonists, opioids and iron therapy. Many non-anemic 
patients with RLS showed reduced levels in brain iron levels compared to healthy control groups in 
several research. The best course of treatment for this group of patients is iron supplementation.  
Oral iron supplementations are the first choice of therapy for patients with low serum ferritin 
levels. However, when serum ferritin levels are normal or high or when oral iron is not tolerated, 
intravenous iron is a better choice. There are many intravenous iron formulations, but low molecular 
weight dextran and ferric carboxymaltose have very efficient effects on the treatment of RLS.  
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Introduction 
Restless legs syndrome (RLS) has been 
described as a neurological disorder, related to 
uncontrolled leg movements, and, in much 
smaller number of patients, it is associated with 
uncontrolled hand movements. Uncontrolled 
limb movements are preceded by a sense of 
discomfort, described by patients as annealing, 
burning, tickling, etc. It occurs more frequently 
during inaction. Therefore, it is a common cause 
of sleep disorders (1-3). In the 17th century, sir 
Thomas Willis noticed the connection between 
sleep disorders and lower extremity discomfort 
among his patients. However, Karl- Axel Ekbom 
first used the term 'restless legs syndrome' in 
1945. That is why this disorder is also known as 
Willis-Ekbom disease (4).  
Unlike some other disorders with similar 
problems, such as polyneuropathy, the 
symptoms of RLS decrease with leg 
movements. In most cases, it is a chronic 
disorder with worsening symptoms, which vary 
in intensity and frequency. Therefore, in patients 
with chronic form of this disorder, symptoms 
occur at least twice a week if patients do not 
follow their therapy (1, 5).  
RLS has prevalence between 8 and 10% (6) in 
adult and 2% in children population (7). The study 
conducted by Manconi et al. has shown that RLS 
occurs more frequently in women, age 35 and 
above, than in men of the same age (8).  
This disorder can be inherited or be a result of a 
clinical condition such as kidney diseases 
(hemodialysis patients) (9), pregnancy 
(evaluated progesterone and estrogen levels, 
iron deficiency) (10), anemia, stomach damage, 
etc. In addition, some substances such as 
neuroleptic drugs, caffeine, lithium, 
metoclopramide, antihistamines, dopaminergic 
agents (1, 11) may increase the risk of developing 
RLS symptoms (Figure 1). 
 
Figure 1. Non-hereditary causes of restless legs syndrome 
Summarized findings from studies to date on the most common diseases/clinical conditions/drugs that are 
associated with restless legs syndrome.
Treatment for RLS depends on its cause. 
Therefore, the treatment can include 
dopaminergic agents, lifestyle changes, iron 
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Compared to the previous European Federation 
of Neurological Societies (EFNS) guidelines on 
the management of RLS from 2004, new 
guidelines from 2012 bring news. Numerous 
drug studies have been made during this period 
and new treatments have been examined that 
could be a potential therapy for RLS. The 
majority of research deals with dopaminergic 
agents, considered the first line therapy. The 
crucial role of iron in pathophysiology of RLS has 
also been confirmed. Alternative forms of 
therapy have been investigated; folate, vitamin 
E, physiotherapy, aerobic training and 
magnesium. Nevertheless, there is still not 
enough evidence of their effectiveness (12). 
Iron in relation to health and diseases  
Iron is one of the most important micronutrient 
in human body.  It has many functions such as a 
role in metabolic processes; it can cause 
oxidative stress because it participates in the 
formation of oxygen radicals (13), and it is a 
cofactor of numerous enzymes (13, 14). 
There are about 4,2 grams of iron in the human 
body, and much of it is bound to hemoglobin 
and involved in oxygen transfer (12). About 10% 
of the iron ingested through food is absorbed in 
the digestive system, mostly in the duodenum 
(15). 
Ferritin is an intracellular protein that stores iron 
and plays an important role in regulating iron 
homeostasis, while transferrin is a glycoprotein 
that binds iron and transports it into the cells (16). 
The major regulator of iron homeostasis is 
hepcidin, 25-amino acid peptide hormone, 
which is mainly secreted by hepatocytes (17, 18). 
Its deregulation is linked with excess iron and 
iron deficiency. Therefore, when level of 
hepcidin is very high, like in case of 
inflammation, the absorption of iron is reduced 
and this can lead to the development of anemia 
(17-19).  
It is proved that brain and liver contain high 
levels of iron (13). The highest concentration of 
brain iron is found in substantia nigra, globus 
pallidus, red nucleus, putamen and dentate 
nucleus of the cerebellum (20, 21). In 
oligodendrocytes, the presence of the 
transferrin has been confirmed, but a greater 
amount of brain iron is nevertheless related with 
ferritin (13, 22). Iron plays a large role in 
neurotransmitter synthesis and mitochondrial 
respiration and its status is regulated at the level 
of the blood- brain barrier (BBB) (13, 23, 24).  
It has long been known that iron excess causes 
hemochromatosis, characterized by skin 
changes, weakness, loss of sex drive, abdominal 
pain and symptoms of diabetes;  but recent 
studies have associated brain iron excess with 
the onset of neurodegenerative diseases such 
as Parkinson's disease. On the other hand, iron 
deficiency in the central nervous system (CNS) is 
associated with irritability, concentration 
disorder, tiredness and it may play a role in the 
pathophysiology of RLS (13). 
Correlation between restless legs 
syndrome and iron 
The first person who noticed that low serum iron 
level could be a risk factor for developing 
restless legs syndrome was Nordlander (25, 26). 
Ekbom observed iron deficiency among his 
patients. Although he noticed repeated 
occurrence of low iron level in RLS, most of his 
patients suffered from uremia, anemia or were 
pregnant women (27). In another research, 
O'Keeffe found low serum iron and ferritin 
values in patients who complained of RLS 
symptoms. It was observed that the lower the 
ferritin level were, the more severe RLS 
symptoms appeared (28, 29). Iron 
supplementation has caused improvement in 
some patients. The potential cause of this is 
altered management of brain iron in patients 
with RLS (30, 31).  
Two studies have shown that almost 2/5 of the 
patients suffering from iron deficiency anemia 
also had symptoms of RLS. Nevertheless, these 
studies used small groups of participants (32, 33). 
However, one study, conducted by Allen et al. 
among the general population, has shown that 
the percentage of people with symptoms of RLS 
is several times higher in the group of 
participants with iron deficiency anemia than in 
the general population (34). Abnormalities in the 
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concentrations of ferritin, transferrin in the 
cerebrospinal fluid (CSF), low CSF ferritin, and 
high CSF transferrin levels have been noticed 
(35). 
Circadian pattern is characteristic for RLS, with 
symptoms being dominant at nighttime. Serum 
iron has a circadian variation, with 30 to 50% drop 
at night. This can lead to clinically significant 
drop in brain iron levels with patients with RLS 
and create the symptoms (36). 
Lower iron concentration in substantia nigra and 
putamen were found in some patients with 
idiopathic RLS and capillary transport of iron in 
the brain probably plays a major role in this. In 
addition, it has been observed that the iron 
levels in substantia nigra increase with aging (37-
39). 
There is a small number of studies that have 
compared the connection between serum 
hepcidin levels and RLS. However, one of them 
found higher prohepcidin (inactive form of 
hepcidin) in putamen and substantia nigra in 
patients with RLS. This opens up the possibility 
of discovering new medications, such as 




Iron deficiency anemia is present in more than 
1/5 of the patients with RLS (34). Accordingly, 
oral and intravenous iron supplements are used 
as therapy for those patients. When serum 
ferritin level is lower than 75 μg/l, oral iron 
supplementation is the therapy of choice. While 
in patients with serum ferritin level higher than 
300 μg/l intravenous iron preparations are a 
better choice (43, 44). O'Keeffe observed among 
his patients, who had different serum ferritin 
values, that oral iron supplements had better 
effect on patients with lower serum ferritin 
values. However, the problem with this study 
was that it did not have a control group (25, 29). 
Furthermore, oral iron supplements have almost 
the same effect whether taken once a day or 
divided into two doses. In addition, in both cases 
these supplementations should be taken with 
vitamin C in order to improve absorption in the 
small intestine (44, 45).  
According to the American Academy of Sleep 
Medicine (AASM) guidelines, iron treatment is 
effective for RLS only in patients who have low 
ferritin levels. In addition, it is preferred oral over 
parenteral iron formulations, because parenteral 
forms are associated with a number of side 
effects that can endanger patients’ life and 
health (46).  
On the other hand, intravenous iron 
supplementations bypass the intestinal- blood 
barrier and restriction of iron absorption (47). 
Intravenous iron forms take precedence over 
oral iron only in two cases. First is when the 
patient is severely bleeding and rapidly losing 
iron, and the second case is when patients have 
problems with oral iron absorption (44, 48).  
There are several intravenous iron formulations 
available: ferric carboxymaltose, iron sucrose, 
iron gluconate, low and high molecular weight 
dextrans (LMW and HMW dextrans), 
ferumoxytol and iron isomaltose (44). LMW 
dextran and ferric carboxymaltose have the best 
clinical evidences for treatment of RLS (1, 44).  
Infusion of 1000 mg LMW dextran improves the 
health of RLS patients with early symptoms and 
significantly increases iron levels in substantia 
nigra (49). Both oral and intravenous iron 
preparations have numerous limitations in the 
treatment of RLS. The most dangerous side 
effect is related to HMW dextran and it involves 
anaphylactic shock. On the other hand, ferric 
carboxymaltose is safe to use because its side 
effects, such as nausea and headache, are much 
milder (50).  
There are not enough studies on intravenous 
sucrose, as well as on most intravenous iron 
preparations. Nevertheless, it is known that 
intravenous sucrose is not effective for patients 
that do not have anemia (50). In addition, for iron 
gluconate, ferumoxytol and iron isomaltose, 
there are insufficient clinical evidences (44, 51) 
(Table 1).. 
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Table 1. Iron preparation limitations in the treatment of restless legs syndrome  
 
Oral ferrous sulfate:                                                      gastrointestinal upset;  
                                                                                        not effective for patients with serum         
                                                                                        ferritin level>75 μg/l 
 
Ferric carboxymaltose:                                               headache 
                                                                                        nausea 
 
Iron sucrose:                                                                    not effective in iron deficiency patients  
                                                                                        without anemia 
 
High molecular weight dextran:                               high incidence of anaphylactic shock 
 
Low molecular weight dextran:                               not so effective in patients with symptoms   
                                                                                        of  late onset RLS  
                                                                               
Iron isomaltose, ferumoxytol, iron gluconate:    not enough clinical evidences 
 
 
Note: Summarized findings from studies to date on oral and intravenous iron preparations for the treatment of restless 
legs syndrome. 
 
Avni et al. have proven in their research that iron 
preparations are safe and effective for RLS. 
However, there is still a great need for further 
research, especially for the research that could 
determine the exact drug dosages and 
therapeutic regimen (43) 
Conclusion 
Numerous studies on the relationship between 
RLS and iron in the body have provided better 
insight into the pathophysiology of this disorder 
and have opened up new possibilities related to 
therapeutic approaches, such as hepcidin 
antagonists. Nevertheless, there are still many 
uncertainties related to iron therapy and a need 
for further research on that topic. The reason is 
the fact that many intravenous iron formulations 
lack sufficient clinical evidences regarding their 
effect on reducing the symptoms of RLS. 
Furthermore, many studies have a small or 
inadequate sample of participants. In addition, 
for many intravenous iron formulations the exact 
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